CN104435484A - Seven connected traditional Chinese medicine packets for treating colorectal cancer - Google Patents
Seven connected traditional Chinese medicine packets for treating colorectal cancer Download PDFInfo
- Publication number
- CN104435484A CN104435484A CN201410662469.1A CN201410662469A CN104435484A CN 104435484 A CN104435484 A CN 104435484A CN 201410662469 A CN201410662469 A CN 201410662469A CN 104435484 A CN104435484 A CN 104435484A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- colorectal cancer
- radix
- traditional chinese
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to seven connected traditional Chinese medicine packets for treating a colorectal cancer. The seven connected traditional Chinese medicine packets are composed of seven small packets, wherein the seven small packets are connected into a whole through cogged tearing openings in the side edges, and respectively contain the following crude drugs by weight: 18-22g of astragalus membranaceus, 6-10g of poria cocos, 13-17g of pinellia ternate, 6-10g of ligusticum wallichii, 4-6g of pseudo-ginseng, 6-10g of radix sophorae flavescentis and 8-12g of sculellaria barbata. The seven connected traditional Chinese medicine packets have the advantages that (1) medicines are conveniently dispensed, the waiting time of patients for taking medicines is shortened, the medicine dispensing efficiency is improved, and the phenomenon of taking excessive medicines is avoided; and (2) the seven connected traditional Chinese medicine packets are significant in treatment effect on the colorectal cancer, low in cost, and free of toxic or side effect almost, and the life time of the patients can be prolonged.
Description
[technical field]
The present invention relates to technical field of Chinese medicines, specifically, is that a kind of Chinese medicine seven for the treatment of colorectal cancer connects bag.
[background technology]
In August, 2008, Chinese medicine management board of country issued " fractional pack prepared slices of Chinese crude drugs medical institutions application guide ".The fractional pack prepared slices of Chinese crude drugs: refer to the prepared slices of Chinese crude drugs that the special small dimension using all-transparent vinyon or non-woven fabrics etc. as packaging material of Manufacture of medicinal slices of TCM enterprise is packed.Have accurate measurement, impurity few, be convenient to the advantages such as preservation.Hospital, according to clinical application custom and demand, buys the prepared slices of Chinese crude drugs of all size fractional pack to manufacturing enterprise.Chinese medicine formula personnel, again according to the prescription of clinician, use the fractional pack prepared slices of Chinese crude drugs to carry out easy and formulation operations fast.The implementation of Chinese medicine fractional pack is a major reform of Chinese medicine industry, carry out precision and standardization that Chinese medicine fractional pack can improve the dosage of drug, the error that before reducing, manual point medicine causes, and wait the time of getting it filled from greatly shortening patient to a great extent.But because fractional pack is packed by people's number number, so loading amount can occur the phenomenon of putting a bag less or putting a bag more, cause the defect on precision, the trouble that increase patient gets it filled and time.
Colorectal cancer comprises the tumor from caecum to the whole intestinal segment of rectum, is common malignant tumor, colorectal cancer due to early clinic symptom not obvious, early diagnostic rate is lower, time obvious to clinical symptoms, belongs to middle and advanced stage more.Taking to perform the operation to intestinal cancer local primary tumo(u)r is at present main therapeutic scheme, and the most important cause of death of Postoperative carcinoma is recurrence and transfer.The ratio of postoperative recurrence and transfer is about 50% in the I phase lower than 10%, II, III phase.Treatment by Chinese herbs accounts for critical role in the treatment of colorectal cancer, can alleviate chemotherapy side effect, promotes postoperative patients's rehabilitation, improves the life quality of patient, reduces tumor recurrence and transfer.
In traditional Chinese medical science ancient documents, do not have the name of " colorectal cancer ", but have many similar records, its etiology and pathogenesis sporadically appears in the relevant discussion such as " mass in the abdomen ", " gathering ", " hemorrhoidal hamorrhage ", " dysentery ", " anorectal carcinoma ".It is generally acknowledged, congenital defect, internal organs deficiency in origin are the basic reasons that colorectal cancer occurs." Ling Shu Miraculous Pivot or Divine Axis all kinds of diseases and ailments begin raw " cloud: " in healthy energy deposits, heresy can not be done, gathering of heresy, and its gas must void." " Jing Yue's complete work gathers " cloud: " people of all spleen kidney deficiencies and debilitating disorder has the disease gathered more; Cover insufficiency of the spleen, middle Jiao does not transport, and suffer from a deficiency of the kidney, the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels is not changed, and healthy energy is not all right, and heresy is let out and occupied it." Chinese patent literature CN201210561474.4 discloses a kind of compound Chinese medicinal preparation for the treatment of advanced CRC, be made up of following component: Radix Astragali 30g, Rhizoma Atractylodis Macrocephalae 15g, Caulis Sargentodoxae 30g, Radix Codonopsis 21g, Poria 21g Semen Coicis 30g, Cortex Magnoliae Officinalis 12g, Radix Paeoniae Alba 18g, Cortex Ailanthi 18g, Semen Myristicae 12g, Herba Artemisiae Anomalae 18g, Herba Scutellariae Barbatae 21g, Herba Hedyotidis Diffusae 30g, Rhizoma Polygonati 30g and Radix Glycyrrhizae 6g.This medicine has certain curative effect to colorectal cancer, but it is many to there are flavour of a drug, carries inconvenience, the shortcoming that therapeutic effect is not good enough.Therefore a kind of flavour of a drug number medicine that is few, easy to carry, that treat intestinal cancer Be very effective is provided to be very necessary.
[summary of the invention]
The object of the invention is for deficiency of the prior art, provide a kind of Chinese medicine seven for the treatment of colorectal cancer to connect bag.
Of the present invention again one object be, provide a kind of described Chinese medicine seven connect bag purposes.
For achieving the above object, the technical scheme that the present invention takes is:
A kind of Chinese medicine seven for the treatment of colorectal cancer connects bag, and it is made up of seven fractional packs; Described seven fractional packs are connected by the groove tearing notch on side; Described seven fractional packs are equipped with the crude drug of following weight respectively: the Radix Astragali 18 ~ 22g, Poria 6 ~ 10g, the Rhizoma Pinelliae 13 ~ 17g, Rhizoma Chuanxiong 6 ~ 10g, Radix Notoginseng 4 ~ 6g, Radix Sophorae Flavescentis 6 ~ 10g, Herba Scutellariae Barbatae 8 ~ 12g.
Described seven fractional packs are equipped with the crude drug of following weight portion respectively: the Radix Astragali 19 ~ 21g, Poria 7 ~ 9g, the Rhizoma Pinelliae 14 ~ 16g, Rhizoma Chuanxiong 7 ~ 9g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 7 ~ 9g, Herba Scutellariae Barbatae 9 ~ 11g.
Described seven fractional packs are equipped with the crude drug of following weight portion respectively: Radix Astragali 20g, Poria 8g, the Rhizoma Pinelliae 15, Rhizoma Chuanxiong 8g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 8g, Herba Scutellariae Barbatae 10g.
For realizing above-mentioned second object, the technical scheme that the present invention takes is:
Described Chinese medicine seven connects the application wrapped in preparation treatment colorectal cancer medicine.
Described colorectal cancer is colon cancer.
Described colorectal cancer is rectal cancer.
Chinese medicine seven of the present invention connects bag and selects the Radix Astragali, Poria, the Rhizoma Pinelliae, Rhizoma Chuanxiong, Radix Notoginseng, Radix Sophorae Flavescentis, Herba Scutellariae Barbatae 7 kinds of Chinese medicines to combine, according to the principle that Chinese medicine counteracts each other, by these medicine efficient combination, make each efficacy of drugs produce synergism, thus reach effect of replenishing QI to invigorate the spleen, heat-clearing and toxic substances removing, blood circulation promoting and dispersing pathogen accumulation.Wherein, Radix Astragali sweet in the mouth, slightly warm in nature, returns liver, spleen, lung, kidney channel, has effect that benefiting QI for strengthening the superficies, arresting sweating are admittedly de-, hold in the palm skin ulcer granulation promoting, inducing diuresis to remove edema; Poria sweet in the mouth, light, property are put down, and have the function of promoting diuresis to eliminate damp pathogen, strengthening the spleen stomach function regulating, mind tranquilizing and the heart calming; The Rhizoma Pinelliae, pungent, temperature, returns spleen, stomach, lung meridian, has drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI effect; The pungent temperature of Rhizoma Chuanxiong, returns liver and gall warp, can blood-activating and qi-promoting, drastically removing blood stasis and resolving static blood; Radix Notoginseng is warm in nature, sweet in the mouth, micro-hardship, can stop blooding by dissipating blood stasis, subduing swelling and relieving pain; Radix Sophorae Flavescentis bitter in the mouth, cold in nature, mild toxicity.Return liver, kidney, large intestine, small intestine meridian, can heat clearing and damp drying, parasite killing diuresis; Herba Scutellariae Barbatae acrid in the mouth, hardship, cold in nature, return lung, liver, kidney channel, can heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.
The invention has the advantages that: (1) seven fractional pack is connected by the gear-like tearing notch on side, simultaneously at each fractional pack front full position reference numerals, link up successively, and indicate the information such as medicine name, weight.The personnel that make up a prescription, when packing, only according to the numeral number in fractional pack front, need block tearing notch at interval of seven numerals, then load plastic bag, decrease patient and wait the time of getting it filled, and avoid occurring taking the phenomenon of putting less more.And dentation tearing notch does not cut off, patient oneself even wraps from seven and tears, and contributes to improving patient and repeatedly throws in same subsides medicine because of not noting when splitting fractional pack or forget input; Numeral in packaging can also calculate remaining Chinese medicine patch number, allows patient know and knows oneself to also have a few note medicine not take.
(2) show according to the result of the test of table 1: compared with model control group, the inhibitory action of each treatment group to colon cancer mouse model tumor growth all has significant difference (P<0.01), and this illustrates that medicine of the present invention is evident in efficacy in treatment colon cancer.In addition, medicine of the present invention does not have significant difference compared with 5-FU group in tumour inhibiting rate, and administration terminates the dead mouse 2 of rear chemotherapy group, this illustrates that curative effect of medication of the present invention is suitable with chemotherapeutics, and while acquisition significant curative effect, also there is the advantage that toxic and side effects is low, obtain unforeseeable technique effect.(3) show according to the result of the test of table 2: compared with model control group, the prolongation effect of each treatment group to colon cancer mouse model life cycle all has significant difference (P<0.01), and this illustrates that medicine of the present invention has significant effect in treatment extends the life cycle of colorectal cancer patients.Each Chinese drug-treated group of the present invention has significant difference (P<0.01) compared with chemotherapy 5-FU group in extending life cycle in addition, and this illustrates that medicine of the present invention has the advantage extending the survival of patients phase while obtaining significant curative effect.
[accompanying drawing explanation]
Accompanying drawing 1 is that Chinese medicine seven of the present invention connects bag schematic diagram.
[detailed description of the invention]
Below detailed description of the invention provided by the invention is elaborated.
The Reference numeral related in accompanying drawing and ingredient as follows:
1. fractional pack 2. groove tearing notch
The Chinese medicine seven that embodiment 1 treats colorectal cancer connects bag ()
Radix Astragali 20g, Poria 8g, Rhizoma Pinelliae 15g, Rhizoma Chuanxiong 8g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 8g, Herba Scutellariae Barbatae 10g.
The Chinese medicine seven that embodiment 2 treats colorectal cancer connects bag (two)
Radix Astragali 20g, Poria 10g, Rhizoma Pinelliae 17g, Rhizoma Chuanxiong 10g, Radix Notoginseng 6g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 3 treats colorectal cancer connects bag (three)
Radix Astragali 20g, Poria 8g, Rhizoma Pinelliae 17g, Rhizoma Chuanxiong 10g, Radix Notoginseng 6g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 4 treats colorectal cancer connects bag (four)
Radix Astragali 20g, Poria 8g, Rhizoma Pinelliae 15g, Rhizoma Chuanxiong 10g, Radix Notoginseng 6g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 5 treats colorectal cancer connects bag (five)
Radix Astragali 20g, Poria 8g, Rhizoma Pinelliae 15g, Rhizoma Chuanxiong 8g, Radix Notoginseng 6g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 6 treats colorectal cancer connects bag (six)
Radix Astragali 20g, Poria 8g, Rhizoma Pinelliae 15g, Rhizoma Chuanxiong 8g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 7 treats colorectal cancer connects bag (seven)
Radix Astragali 18g, Poria 6g, Rhizoma Pinelliae 13g, Rhizoma Chuanxiong 6g, Radix Notoginseng 4g, Radix Sophorae Flavescentis 6g, Herba Scutellariae Barbatae 8g.
The Chinese medicine seven that embodiment 8 treats colorectal cancer connects bag (eight)
Radix Astragali 20g, Poria 6g, Rhizoma Pinelliae 15g, Rhizoma Chuanxiong 7g, Radix Notoginseng 4g, Radix Sophorae Flavescentis 10g, Herba Scutellariae Barbatae 12g.
The Chinese medicine seven that embodiment 9 treats colorectal cancer connects bag (nine)
Radix Astragali 18g, Poria 8g, Rhizoma Pinelliae 13g, Rhizoma Chuanxiong 7g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 9g, Herba Scutellariae Barbatae 11g.
The Chinese medicine seven that embodiment 10 treats colorectal cancer connects bag (ten)
Radix Astragali 21g, Poria 7g, Rhizoma Pinelliae 16g, Rhizoma Chuanxiong 7g, Radix Notoginseng 6g, Radix Sophorae Flavescentis 6g, Herba Scutellariae Barbatae 9g.
The zoopery of embodiment 11 Drug therapy intestinal cancer of the present invention
1 material
1.1 animals and tumor strain
SPF level nude mice, male, body weight 22 ± 2g, is purchased from Shanghai City Si Laike laboratory animal company limited, credit number: SCXK (Shanghai) 2003-2003; SW629 cell (human colon cancer cell), purchased from Shanghai Fu Meng gene biological Science and Technology Ltd..
1.2 medicine and reagent
Chinese medicine prepared by embodiment 1, it is 2g/ml that conventional method decocts to crude drug content, seals, cryopreservation; 5-fluorouracil, 250mg/10ml, is purchased from Hengrui Medicine Co., Ltd., Jiangsu Prov..
2 methods
The 2.1 tumor modeling of nude mice Mus subcutaneous transplantation and packet transaction
1. modeling: with the SW629 cell of exponential phase in cultivation, be prepared into tumor cell suspension with after trypsinization, adjustment oncocyte concentration is 1 × 10
6/ ml, 2 nude mice cervical regions are only injected subcutaneous by 0.2ml/, repeated inoculation 1 time after 4d, repeatedly go down to posterity into solid tumor after becoming tumor, when inoculation position tumor grows to diameter 10 ~ 15mm, tumor is stripped out from cervical region hypodermis is complete, and choose well-grown, in pale red, the tumor tissue of flesh of fish shape, it is for subsequent use that the fritter being cut into diameter 1.5 ~ 2.0mm is placed in aseptic 0.9% sodium chloride solution.Separately get 60 nude mices, after Patients Under Ketamine Anesthesia success, 75% ethanol disinfection nude mice skin of back, is inoculated in nude mice dorsal sc by the tumor tissue 3 ~ 4 pieces cut in batches.
2. divide into groups and process: postvaccinal nude mice is divided into following 5 groups at random:
Model control group (calling model group in the following text): model of colon cancer Mus 12, gavages normal saline 5ml/ (kgd);
Western medicine 5-fluorouracil group (calling 5-FU group in the following text): model of colon cancer Mus 12, lumbar injection 5-fluorouracil 30mg/ (kgd);
Chinese medicine low dose group: model of colon cancer Mus 12, gavages medicine 20ml/ (kgd) prepared by the embodiment of the present invention 1 respectively;
Dosage group in Chinese medicine: model of colon cancer Mus 12, gavages medicine 30ml/ (kgd) prepared by the embodiment of the present invention 1 respectively;
Chinese medicine high dose group: model of colon cancer Mus 12, gavages medicine 40ml/ (kgd) prepared by the embodiment of the present invention 1 respectively.
Above-mentioned each group inoculate respectively after within the 1st day, play beginning administration, to the 12nd day terminate.
2.2 Indexs measure
After last administration 48h, Mus is put to death in dislocation, and excision transplanted tumor, weighs tumor kind.Tumour inhibiting rate (%) IR=(1-administration group tumor weight-average value/model control group tumor kind average) × 100%.Relatively embody medicine to colon cancer mouse model preventive and therapeutic effect by what weigh tumor, data represent with mean ± standard deviation (x ± s), adopt SPSS15.0 software to carry out variance analysis.
3 results and analysis
Result of the test according to table 1 shows: compared with model control group, the inhibitory action of each treatment group to colon cancer mouse model tumor growth all has significant difference (P<0.01), and this illustrates that medicine of the present invention is evident in efficacy in treatment colon cancer.In addition, medicine of the present invention does not have significant difference compared with 5-FU group in tumour inhibiting rate, and administration terminates the dead mouse 2 of rear chemotherapy group, this illustrates that curative effect of medication of the present invention is suitable with chemotherapeutics, and while acquisition significant curative effect, also there is the advantage that toxic and side effects is low, obtain unforeseeable technique effect.
Result of the test according to table 2 shows: compared with model control group, the prolongation effect of each treatment group to colon cancer mouse model life cycle all has significant difference (P<0.01), and this illustrates that medicine of the present invention has significant effect in treatment extends the life cycle of colorectal cancer patients.Each Chinese drug-treated group of the present invention has significant difference (P<0.01) compared with chemotherapy 5-FU group in extending life cycle in addition, and this illustrates that medicine of the present invention has the advantage extending the survival of patients phase while obtaining significant curative effect.
Table 1 Chinese medicine seven of the present invention connects the impact of bag on colon cancer mouse model
| Group | Sample size (start/end) | Tumor weight in wet base (g) | Average tumour inhibiting rate (%) | P value |
| Model control group | 12/12 | 1.62±0.25 | ||
| 5-FU group | 12/10 | 0.75±0.27 ** | 53.71 | P<0.01 |
| Chinese medicine low dose group | 12/12 | 0.86±0.19 ** | 46.92 | P<0.01 |
| Dosage group in Chinese medicine | 12/12 | 0.73±0.21 ** | 54.94 | P<0.01 |
| Chinese medicine high dose group | 12/12 | 0.61±0.27 ** | 62.35 | P<0.01 |
Compare with model group, * * P<0.01.
Table 2 pharmaceutical composition of the present invention affected the life cycle of colon cancer mouse model
| Group | Life cycle (d) | P value |
| Model control group | 29±7.1 | |
| 5-FU group | 47±4.5 ** | P<0.01 |
| Chinese medicine low dose group | 66±3.5 ** | P<0.01 |
| Dosage group in Chinese medicine | 68±2.6 **￥￥ | P<0.01 |
| Chinese medicine high dose group | 70±2.6 **￥￥ | P<0.01 |
Compared with model control group, * * P<0.01.
， $$P<0.01 is compared with chemotherapy group.
Embodiment 12 Chinese medicine seven of the present invention connects bag schematic diagram
Please refer to Fig. 1, Fig. 1 is that Chinese medicine seven of the present invention connects bag schematic diagram, and described Chinese medicine seven connects bag and is made up of seven fractional packs 1, and described fractional pack 1 is connected by the groove tearing notch 2 of side.Operator, when packing, only according to the numeral number in fractional pack 1 front, need block groove tearing notch 2 at interval of seven numerals, then load plastic bag, decrease patient and wait the time of getting it filled, and avoid occurring taking the phenomenon of putting less more.Patient can calculate remaining Chinese medicine patch number according to the numeral number on fractional pack 1, allow patient know and know oneself to also have a few note medicine not take, avoid repeatedly throwing in or forgetting input.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the inventive method; can also make some improvement and supplement, these improve and supplement and also should be considered as protection scope of the present invention.
Claims (6)
1. a Chinese medicine seven for the treatment of colorectal cancer connects bag, and it is characterized in that, described Chinese medicine seven connects bag and is made up of seven fractional packs; Described seven fractional packs are connected by the groove tearing notch on side; Described seven fractional packs are equipped with the crude drug of following weight respectively: the Radix Astragali 18 ~ 22g, Poria 6 ~ 10g, the Rhizoma Pinelliae 13 ~ 17g, Rhizoma Chuanxiong 6 ~ 10g, Radix Notoginseng 4 ~ 6g, Radix Sophorae Flavescentis 6 ~ 10g, Herba Scutellariae Barbatae 8 ~ 12g.
2. Chinese medicine seven according to claim 1 connects bag, it is characterized in that, described seven fractional packs are equipped with the crude drug of following weight portion respectively: the Radix Astragali 19 ~ 21g, Poria 7 ~ 9g, the Rhizoma Pinelliae 14 ~ 16g, Rhizoma Chuanxiong 7 ~ 9g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 7 ~ 9g, Herba Scutellariae Barbatae 9 ~ 11g.
3. Chinese medicine seven according to claim 1 connects bag, and it is characterized in that, described seven fractional packs are equipped with the crude drug of following weight portion respectively: Radix Astragali 20g, Poria 8g, the Rhizoma Pinelliae 15, Rhizoma Chuanxiong 8g, Radix Notoginseng 5g, Radix Sophorae Flavescentis 8g, Herba Scutellariae Barbatae 10g.
4. the arbitrary described Chinese medicine seven of claim 1-3 connects the application wrapped in preparation treatment colorectal cancer medicine.
5. application according to claim 4, is characterized in that, described colorectal cancer is colon cancer.
6. application according to claim 4, is characterized in that, described colorectal cancer is rectal cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410662469.1A CN104435484A (en) | 2014-11-19 | 2014-11-19 | Seven connected traditional Chinese medicine packets for treating colorectal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410662469.1A CN104435484A (en) | 2014-11-19 | 2014-11-19 | Seven connected traditional Chinese medicine packets for treating colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435484A true CN104435484A (en) | 2015-03-25 |
Family
ID=52882745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410662469.1A Pending CN104435484A (en) | 2014-11-19 | 2014-11-19 | Seven connected traditional Chinese medicine packets for treating colorectal cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435484A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784406A (en) * | 2015-05-05 | 2015-07-22 | 黄玉莲 | Traditional Chinese medicine composition for treating rectal cancer and preparation method |
| CN104857447A (en) * | 2015-05-29 | 2015-08-26 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating intestinal cancer |
| CN105456815A (en) * | 2015-12-12 | 2016-04-06 | 牟青杰 | Traditional Chinese medicine for inhibiting tumors and preparation method of traditional Chinese medicine |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252300A (en) * | 1999-10-10 | 2000-05-10 | 黄晓维 | Compounding method of carcinomatosis resisting medicine |
| CN101361698A (en) * | 2008-08-01 | 2009-02-11 | 陶怀泉 | Five-subpackage medicine-package of prepared traditional Chinese medicine in routine dose |
| CN201260781Y (en) * | 2008-08-01 | 2009-06-24 | 陶怀泉 | Routine dose 5-linked separated medicine bag for prepared Chinese herbal medicine |
| CN102058744A (en) * | 2010-11-25 | 2011-05-18 | 代龙 | Chinese medicinal composition for treating malignant tumor and preparation method thereof |
| CN103191191A (en) * | 2013-04-20 | 2013-07-10 | 杨凌无为制药集团有限公司 | Preparation method of traditional Chinese medicine composition for treating advanced non-small cell lung cancers |
-
2014
- 2014-11-19 CN CN201410662469.1A patent/CN104435484A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252300A (en) * | 1999-10-10 | 2000-05-10 | 黄晓维 | Compounding method of carcinomatosis resisting medicine |
| CN101361698A (en) * | 2008-08-01 | 2009-02-11 | 陶怀泉 | Five-subpackage medicine-package of prepared traditional Chinese medicine in routine dose |
| CN201260781Y (en) * | 2008-08-01 | 2009-06-24 | 陶怀泉 | Routine dose 5-linked separated medicine bag for prepared Chinese herbal medicine |
| CN102058744A (en) * | 2010-11-25 | 2011-05-18 | 代龙 | Chinese medicinal composition for treating malignant tumor and preparation method thereof |
| CN103191191A (en) * | 2013-04-20 | 2013-07-10 | 杨凌无为制药集团有限公司 | Preparation method of traditional Chinese medicine composition for treating advanced non-small cell lung cancers |
Non-Patent Citations (1)
| Title |
|---|
| 李世荣: "《大肠癌早期诊断、治疗和预防》", 28 February 2000, 科学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784406A (en) * | 2015-05-05 | 2015-07-22 | 黄玉莲 | Traditional Chinese medicine composition for treating rectal cancer and preparation method |
| CN104857447A (en) * | 2015-05-29 | 2015-08-26 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating intestinal cancer |
| CN105456815A (en) * | 2015-12-12 | 2016-04-06 | 牟青杰 | Traditional Chinese medicine for inhibiting tumors and preparation method of traditional Chinese medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102284049A (en) | Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof | |
| CN104435484A (en) | Seven connected traditional Chinese medicine packets for treating colorectal cancer | |
| CN103301423A (en) | Traditional Chinese medicine for treating female infertility | |
| CN104435686A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN104161978A (en) | Traditional Chinese medicine for treating menopausal Sjogren syndrome | |
| CN103599474A (en) | Traditional Chinese medicinal composition for treating poor sleep quality | |
| CN102743703B (en) | Medicament for treating cervical spondylosis and preparation method thereof | |
| CN103830487A (en) | Traditional Chinese medicine for treating diarrhea associated with menstruation | |
| CN103721237A (en) | Traditional Chinese medicine composition for treating hypomenorrhea | |
| CN106902307A (en) | A kind of Chinese medicine composition and usage for treating malignant tumor of lung | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN106729327B (en) | Traditional Chinese medicine composition for treating qi-blood deficiency and kidney deficiency type irregular menstruation | |
| CN106511689B (en) | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction | |
| CN105012552A (en) | Traditional Chinese medicine for treating wind-prevailing migratory arthralgia type rheumatic arthritis and preparation method | |
| CN104173913A (en) | Traditional Chinese medicine for treating chronic cholecystitis | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN103301415A (en) | Medicinal composition for preventing and treating intrauterine adhesion after induced abortion operation and application thereof | |
| CN105031552A (en) | Traditional Chinese medicine composition for treating gynecological tumors | |
| CN105833181A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparing method thereof | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof | |
| CN105168665A (en) | Traditional Chinese medicinal composition for treating gynecological tumor | |
| CN105168774A (en) | Traditional Chinese medicine preparation for treating scapulohumeral periarthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |
|
| WD01 | Invention patent application deemed withdrawn after publication |